Krystal Biotech, Inc. (KRYS)

Krystal Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	204.83	89.16	10.93	-139.98	-69.57
Depreciation & Amortization	2.45	3.21	4.81	3.39	2.77
Loss (Gain) From Sale of Assets	-	-	-100	-	-
Loss (Gain) From Sale of Investments	-6.45	-7.78	-7.28	0.1	-
Stock-Based Compensation	54.51	49.13	39.93	33.23	15.32
Other Operating Activities	-18.06	4.15	1.32	0.03	1.04
Change in Accounts Receivable	-22.12	-62.71	-42.04	-	-
Change in Inventory	-6.29	-11.91	-4.48	-	-
Change in Accounts Payable	0.83	1.01	-0.1	-1.25	0.71
Change in Income Taxes	-12.39	-1.62	-	-	-
Change in Other Net Operating Assets	3.55	60.76	8.09	3.91	1.79
Operating Cash Flow	200.87	123.42	-88.8	-100.57	-47.94
Operating Cash Flow Growth	62.75%	-	-	-	-
Capital Expenditures	-11.95	-4.24	-11.8	-52.98	-68.34
Sale of Property, Plant & Equipment	0.44	-	100	-	-
Investment in Securities	-46.9	-159.2	-5.56	-61.1	-158.43
Investing Cash Flow	-58.42	-163.44	82.64	-114.08	-226.77
Issuance of Common Stock	22.66	32.4	203.5	36	355.65
Repurchase of Common Stock	-13.96	-5.39	-0.75	-0.65	-
Other Financing Activities	-	-	-	-	-7.96
Financing Cash Flow	8.71	27.01	202.75	35.35	347.69
Foreign Exchange Rate Adjustments	0.29	-0.46	-0.16	-0.04	-
Net Cash Flow	151.44	-13.46	196.43	-179.35	72.98
Free Cash Flow	188.91	119.18	-100.6	-153.55	-116.27
Free Cash Flow Growth	58.51%	-	-	-	-
Free Cash Flow Margin	48.55%	41.02%	-198.43%	-	-
Free Cash Flow Per Share	6.31	4.01	-3.63	-6.02	-5.24
Cash Income Tax Paid	15.67	5.67	-	-	-
Levered Free Cash Flow	93.93	92.99	-74.54	-90.02	-85.35
Unlevered Free Cash Flow	93.93	92.99	-74.54	-90.02	-84.41
Change in Working Capital	-36.42	-14.46	-38.52	2.66	2.51

Updated Feb 17, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q